2004
DOI: 10.1021/bp030070k
|View full text |Cite
|
Sign up to set email alerts
|

Antibodies and Genetically Engineered Related Molecules: Production and Purification

Abstract: Antibodies and antibody derivatives constitute 20 % of biopharmaceutical products currently in development, and despite early failures of murine products, chimeric and humanized monoclonal antibodies are now viable therapeutics. A number of genetically engineered antibody constructions have emerged, including molecular hybrids or chimeras that can deliver a powerful toxin to a target such as a tumor cell. However, the general use in clinical practice of antibody therapeutics is dependent not only on the availa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
208
0
7

Year Published

2006
2006
2014
2014

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 328 publications
(216 citation statements)
references
References 175 publications
1
208
0
7
Order By: Relevance
“…Purification of pharmaceutical and other high-value proteins is an ongoing concern for biotechnologists, because commercial downstream processes used today are extremely complex and costly, accounting for as much as 50-80% of total manufacturing costs (25). In particular, the cost of protein A-based immunoadsorbent, a standard reagent used for industrial purification of monoclonal antibodies, is so high that the columns have to be reused up to 50 times, resulting in significant costs due to multiple cleanings and revalidation of the columns.…”
Section: Discussionmentioning
confidence: 99%
“…Purification of pharmaceutical and other high-value proteins is an ongoing concern for biotechnologists, because commercial downstream processes used today are extremely complex and costly, accounting for as much as 50-80% of total manufacturing costs (25). In particular, the cost of protein A-based immunoadsorbent, a standard reagent used for industrial purification of monoclonal antibodies, is so high that the columns have to be reused up to 50 times, resulting in significant costs due to multiple cleanings and revalidation of the columns.…”
Section: Discussionmentioning
confidence: 99%
“…Small ligands such as peptides have potential advantages in chromatography processes because they can be more stable and less immunogenic than protein ligands, can be constructed with a wide variety of bio-specificity and their production cost is low (Fassina et al, 1996;Yang et al, 2005). Although several Protein-A Mimetic peptide ligands have been synthesized, screened and evaluated for their suitability in chromatography process development (Fassina, 2000;Roque et al, 2004;Yang et al, 2005), only a few have been extensively studied. For example, PAM peptide TG19318 (Fassina et al, 1998), a tetrameric peptide ligand, was successfully investigated for the isolation of various classes of human Igs (IgG, IgA, IgE, IgM) (Huse et al, 2002) from human serum and bacterial cell culture broths.…”
Section: Introductionmentioning
confidence: 99%
“…Novel affinity-based separations have emerged from the development of synthetic ligands including peptides obtained by combinatorial libraries and artificial ligands generated by de novo process designs (Roque et al, 2004(Roque et al, , 2007, although so far with limited applicability by big pharma companies. Nonchromatographic alternatives including membrane chromatography, tangential flow filtration, high gradient magnetic fishing, aqueous two-phase extraction, precipitation, and crystallization have also been described (Przybycien et al, 2004;Low et al, 2007;Azevedo et al, 2009).…”
Section: Introductionmentioning
confidence: 99%